Long-term follow-up of Korean people with CADASIL, an inherited brain disease
Follows Korean people with CADASIL over 10 years to learn how it progresses.
Plain-language title generated from the registry record
Registry title: Long-term Prospective Study of Korean CADASIL Patients
Key facts
- Where
- Jeju City, South KoreaSee the site
Where in South Korea
- Jeju National University HospitalJeju City, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jeju National University Hospital
- Trial code
- NCT07497867
- Record updated
- 14 May 2026
- Original description
K-CADASIL is a 10-year prospective study of 500 Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic brain disease that causes stroke and dementia. The investigators will track symptoms, brain scans, memory tests, and gene information to understand disease progression in Koreans and identify better treatments. Participants will visit clinics regularly for check-ups and blood tests. This study aims to help improve care for CADASIL patients and families worldwide.Read full original descriptionShow less
Long-term Prognosis of Korean Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy(CADASIL) Patients: A Multicenter Prospective Study
K-CADASIL is a 10-year prospective study of 500 Korean patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic brain disease that causes stroke and dementia. The investigators will track symptoms, brain scans, memory tests, and gene information to understand disease progression in Koreans and identify better treatments. Participants will visit clinics regularly for check-ups and blood tests. This study aims to help improve care for CADASIL patients and families worldwide.
Inclusion: Age ≥ 19 years; CADASIL suspected or confirmed by genetic testing (NOTCH3 mutation); Able to provide written informed consent (participant or legally authorized representative).
Exclusion: Contraindication to MRI (claustrophobia, metal implants, pacemaker); Acute ischemic or hemorrhagic stroke within 180 days prior to enrollment.